Skip to main content
Erschienen in: Environmental Health and Preventive Medicine 3/2015

01.05.2015 | Regular Article

The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma

verfasst von: N. M. Abdel-Hamid, O. M. Mohafez, M. H. Nazmy, A. Farhan, K. Thabet

Erschienen in: Environmental Health and Preventive Medicine | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate the effect of Lawsonia inermis total methanolic extract (LIE) and octreotide (OC) on hepatocellular carcinoma (HCC) progression, depending on somatostatin receptor 2 (SSTR-2) and Alfa fetoprotein (AFP) perturbations.

Methods

Sixty albino mice, divided into five groups (12/each); all except control were injected with single diethyl nitrosamine (DENA) dose of 90 mg/kg body weight, intraperitoneally (IP). DENA group was killed at the last day of week 18. LIE group was given 200 mg/100 ml drinking water from first day of DENA injection until end of week 18. OC group received OC (0.1 mg/kg body weight, twice daily by subcutaneous injection, SC from the first day of week 17 till end of week 18. LIE + OC was given medications till the last day of week 18. Serum AFP, liver tissue SSTR-2 mRNA, its protein expression, reduced glutathione (GSH) and malondialdehyde (MDA) were analyzed.

Results

A significant increase in plasma AFP and hepatic mRNA, associated to liver tissue neoplastic changes, SSTR-2 expression and MDA with decreased hepatic GSH were observed in DENA group. These changes were significantly improved by LIE and/or OC.

Conclusions

LIE and/or OC treatment has effective chemopreventive action due to their ability to alleviate oxidative stress, desensitizing cellular growth receptor to SST.
Literatur
2.
Zurück zum Zitat Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211.CrossRefPubMed Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211.CrossRefPubMed
3.
Zurück zum Zitat Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42–9.CrossRefPubMed Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42–9.CrossRefPubMed
4.
Zurück zum Zitat Abdel-Hamid NM, Abdel-Ghany MI, Nazmy MH, Amgad SW. Can methanolic extract of Nigella sativa seed affect glyco-regulatory enzymes in experimental hepatocellular carcinoma? Environ Health Prev Med. 2013;18(1):49–56.CrossRefPubMedCentralPubMed Abdel-Hamid NM, Abdel-Ghany MI, Nazmy MH, Amgad SW. Can methanolic extract of Nigella sativa seed affect glyco-regulatory enzymes in experimental hepatocellular carcinoma? Environ Health Prev Med. 2013;18(1):49–56.CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L, Susini C. Critical role of src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell. 2003;14(9):3911–28.CrossRefPubMedCentralPubMed Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L, Susini C. Critical role of src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell. 2003;14(9):3911–28.CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993;60(2):245–64.CrossRefPubMed Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993;60(2):245–64.CrossRefPubMed
7.
Zurück zum Zitat Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2(12):999–1017.CrossRefPubMed Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2(12):999–1017.CrossRefPubMed
8.
Zurück zum Zitat Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781–93.CrossRefPubMed Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781–93.CrossRefPubMed
9.
Zurück zum Zitat Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2014;35(3):2497–502.CrossRefPubMed Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2014;35(3):2497–502.CrossRefPubMed
10.
Zurück zum Zitat Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2014;35(3):2497–502.CrossRefPubMed Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol. 2014;35(3):2497–502.CrossRefPubMed
11.
Zurück zum Zitat Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci. 2002;18(1–2):15–27.CrossRefPubMed Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci. 2002;18(1–2):15–27.CrossRefPubMed
12.
Zurück zum Zitat Dasgupta P, Singh A, Mukherjee R. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol Pharm Bull. 2002;25(1):29–36.CrossRefPubMed Dasgupta P, Singh A, Mukherjee R. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol Pharm Bull. 2002;25(1):29–36.CrossRefPubMed
13.
Zurück zum Zitat Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002;13(10):451–7.CrossRefPubMed Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002;13(10):451–7.CrossRefPubMed
14.
Zurück zum Zitat Gupta A. Quality standards of Indian medicinal plants. Indian Counc Med Res. 2003;1:123–9. Gupta A. Quality standards of Indian medicinal plants. Indian Counc Med Res. 2003;1:123–9.
15.
Zurück zum Zitat Lavhate MSMS. A review: nutritional and therapeutic potential of Ailanthus excelsa. Pharmacog Rev. 2007;1(1):105–13. Lavhate MSMS. A review: nutritional and therapeutic potential of Ailanthus excelsa. Pharmacog Rev. 2007;1(1):105–13.
16.
Zurück zum Zitat Khodaparast H. HMaZD: phenolic compounds and antioxidant activity of henna leaves extracts. Dairy Food Sci. 2007;2(1):38–41. Khodaparast H. HMaZD: phenolic compounds and antioxidant activity of henna leaves extracts. Dairy Food Sci. 2007;2(1):38–41.
17.
Zurück zum Zitat Madhava Chetty K, Sivaji K, Tulsi Rao K. Flowering plants of Chittoor district, Andhra Pradesh, India. 1st ed. Tirupati: Students Offset printers; 2008. Madhava Chetty K, Sivaji K, Tulsi Rao K. Flowering plants of Chittoor district, Andhra Pradesh, India. 1st ed. Tirupati: Students Offset printers; 2008.
18.
Zurück zum Zitat Mikhaeil BR, Badria FA, Maatooq GT, Amer MM. Antioxidant and immunomodulatory constituents of henna leaves. Z Naturforsch C. 2004;59(7–8):468–76.PubMed Mikhaeil BR, Badria FA, Maatooq GT, Amer MM. Antioxidant and immunomodulatory constituents of henna leaves. Z Naturforsch C. 2004;59(7–8):468–76.PubMed
19.
Zurück zum Zitat Sharma ASNaR. Studies on mode of action of hexaammine co(iii) chloride against diethylnitrosamine-induced hepatocarcinogenesis in mice. J Biochem Mol Toxicol. 2009;3(3):193–201. Sharma ASNaR. Studies on mode of action of hexaammine co(iii) chloride against diethylnitrosamine-induced hepatocarcinogenesis in mice. J Biochem Mol Toxicol. 2009;3(3):193–201.
20.
Zurück zum Zitat Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, Liang LJ. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy. 2009;55(5):312–20.CrossRefPubMed Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, Liang LJ. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy. 2009;55(5):312–20.CrossRefPubMed
21.
Zurück zum Zitat Dasgupta TRA, Yadava PK. Modulatory effect of Henna leaf (Lawsonia inermis) on drug metabolising phase I and phase II enzymes, antioxidant enzymes, lipid peroxidation and chemically induced skin and forestomach papillomagenesis in mice. Mol Cell Biochem. 2003;245:11–22.CrossRefPubMed Dasgupta TRA, Yadava PK. Modulatory effect of Henna leaf (Lawsonia inermis) on drug metabolising phase I and phase II enzymes, antioxidant enzymes, lipid peroxidation and chemically induced skin and forestomach papillomagenesis in mice. Mol Cell Biochem. 2003;245:11–22.CrossRefPubMed
22.
Zurück zum Zitat Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
23.
Zurück zum Zitat Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86(1):271–8.CrossRefPubMed Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86(1):271–8.CrossRefPubMed
25.
26.
Zurück zum Zitat Bhosale PML, Ingle AD, Gadre RB, Rao KVK. Protective effect of Rhodotorula glutinis NCIM3353 on the development of hepatic preneoplastic lesions. Curr Sci. 2002;83:303–8. Bhosale PML, Ingle AD, Gadre RB, Rao KVK. Protective effect of Rhodotorula glutinis NCIM3353 on the development of hepatic preneoplastic lesions. Curr Sci. 2002;83:303–8.
27.
28.
Zurück zum Zitat Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):145–59.CrossRefPubMed Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):145–59.CrossRefPubMed
29.
Zurück zum Zitat Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42(3):442–7.CrossRefPubMedCentralPubMed Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42(3):442–7.CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Reynaert H, Rombouts K, Jia Y, Urbain D, Chatterjee N, Uyama N, Geerts A. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol. 2005;146(1):77–88.CrossRefPubMedCentralPubMed Reynaert H, Rombouts K, Jia Y, Urbain D, Chatterjee N, Uyama N, Geerts A. Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells. Br J Pharmacol. 2005;146(1):77–88.CrossRefPubMedCentralPubMed
31.
32.
Zurück zum Zitat Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000;94(3–4):205–10.CrossRefPubMed Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000;94(3–4):205–10.CrossRefPubMed
33.
Zurück zum Zitat Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53(8):1180–9.CrossRefPubMedCentralPubMed Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53(8):1180–9.CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Sivaramakrishnan V, Shilpa PN, Praveen Kumar VR, Niranjali Devaraj S. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol–Morin. Chem Biol Interact. 2008;171(1):79–88.CrossRefPubMed Sivaramakrishnan V, Shilpa PN, Praveen Kumar VR, Niranjali Devaraj S. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol–Morin. Chem Biol Interact. 2008;171(1):79–88.CrossRefPubMed
36.
Zurück zum Zitat Yadav AS, Bhatnagar D. Chemo-preventive effect of Star anise in N-nitrosodiethylamine initiated and phenobarbital promoted hepato-carcinogenesis. Chem Biol Interact. 2007;169(3):207–14.CrossRefPubMed Yadav AS, Bhatnagar D. Chemo-preventive effect of Star anise in N-nitrosodiethylamine initiated and phenobarbital promoted hepato-carcinogenesis. Chem Biol Interact. 2007;169(3):207–14.CrossRefPubMed
37.
Zurück zum Zitat Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733–42.CrossRefPubMed Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733–42.CrossRefPubMed
38.
Zurück zum Zitat Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006;17(6):601–8.CrossRefPubMed Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. 2006;17(6):601–8.CrossRefPubMed
39.
Zurück zum Zitat Liu HL, Huo L, Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin. 2004;25(10):1380–6.PubMed Liu HL, Huo L, Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin. 2004;25(10):1380–6.PubMed
40.
Zurück zum Zitat Xie Y, Tang CW, Wang CH. Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2. Ai Zheng. 2005;24(8):965–9.PubMed Xie Y, Tang CW, Wang CH. Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2. Ai Zheng. 2005;24(8):965–9.PubMed
41.
Zurück zum Zitat Ma Q, Meng LQ, Liu JC, Hu JP, Ge J, Wan YL, Jiang S. Octreotide induces apoptosis of human hepatoma cells by the mechanism of facilitating the Fas/FasL gene expression therein. Zhonghua Yi Xue Za Zhi. 2008;88(10):716–8.PubMed Ma Q, Meng LQ, Liu JC, Hu JP, Ge J, Wan YL, Jiang S. Octreotide induces apoptosis of human hepatoma cells by the mechanism of facilitating the Fas/FasL gene expression therein. Zhonghua Yi Xue Za Zhi. 2008;88(10):716–8.PubMed
42.
Zurück zum Zitat Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, Kouroumalis E. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep. 2002;9(4):903–7.PubMed Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, Kouroumalis E. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep. 2002;9(4):903–7.PubMed
43.
Zurück zum Zitat Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36(3):687–91.CrossRefPubMed Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36(3):687–91.CrossRefPubMed
44.
Zurück zum Zitat Kouroumalis E, Samonakis D, Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology. 2003;37(2):477.CrossRefPubMed Kouroumalis E, Samonakis D, Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology. 2003;37(2):477.CrossRefPubMed
45.
Zurück zum Zitat Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86(8):3809–14.CrossRefPubMed Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab. 2001;86(8):3809–14.CrossRefPubMed
46.
Zurück zum Zitat Dournaud P, Boudin H, Schonbrunn A, Tannenbaum GS, Beaudet A. Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin. J Neurosci. 1998;18(3):1056–71.PubMed Dournaud P, Boudin H, Schonbrunn A, Tannenbaum GS, Beaudet A. Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: evidence for regulation of cell surface receptors by endogenous somatostatin. J Neurosci. 1998;18(3):1056–71.PubMed
47.
Zurück zum Zitat Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41(7):1256–63.PubMed Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41(7):1256–63.PubMed
48.
Zurück zum Zitat Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A. 2003;100(1):155–60.CrossRefPubMedCentralPubMed Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A. 2003;100(1):155–60.CrossRefPubMedCentralPubMed
49.
Zurück zum Zitat Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ. 2007;14(2):197–208.CrossRefPubMed Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ. 2007;14(2):197–208.CrossRefPubMed
50.
Zurück zum Zitat Priya R, Ilavenil S, Kaleeswaran B, Srigopalram S, Ravikumar S. Effect of Lawsonia inermis on tumor expression induced by Dalton’s lymphoma ascites in Swiss albino mice. Saudi J Biol Sci. 2011;18(4):353–9.CrossRefPubMedCentralPubMed Priya R, Ilavenil S, Kaleeswaran B, Srigopalram S, Ravikumar S. Effect of Lawsonia inermis on tumor expression induced by Dalton’s lymphoma ascites in Swiss albino mice. Saudi J Biol Sci. 2011;18(4):353–9.CrossRefPubMedCentralPubMed
Metadaten
Titel
The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma
verfasst von
N. M. Abdel-Hamid
O. M. Mohafez
M. H. Nazmy
A. Farhan
K. Thabet
Publikationsdatum
01.05.2015
Verlag
Springer Japan
Erschienen in
Environmental Health and Preventive Medicine / Ausgabe 3/2015
Print ISSN: 1342-078X
Elektronische ISSN: 1347-4715
DOI
https://doi.org/10.1007/s12199-015-0451-9

Weitere Artikel der Ausgabe 3/2015

Environmental Health and Preventive Medicine 3/2015 Zur Ausgabe